

*Genes and proteins are listed under "genes/proteins" for each species, except those from all mammalian species, which are grouped under "Mammalian genes/proteins."*

- Abasic site repair, 43–85, 88, 90  
 mitochondrial, 68, 69
- Apoptosis, 119, 190, 242, 257, 273, 286, 290,  
 330, 345, 346, 390
- Apurinic/apyrimidinic endonuclease (AP  
 endo), 45–58, 60, 61, 64, 66, 67,  
 69, 87–105, 197  
 human variants, 52, 53
- Arabidopsis* Arp protein, 88
- Ataxia telangiectasia (AT; *see also* Mamma-  
 lian ATM), 126, 138, 148, 163,  
 164, 194, 225, 296, 297, 316, 367,  
 386, 387  
 AT-like disorder (ATLD; *see also* Mamma-  
 lian MRE11), 165, 194  
 AT variant, *see* Nijmegen breakage syn-  
 drome
- Bacteriophage, 1–19  
 base-excision repair (BER), 1, 2, 7, 13  
 damage recognition, 14, 15  
 double-strand break repair, 1, 3, 9  
 error-prone repair, 4  
 $\lambda$ , 1  
 $\lambda$  phosphatase, 149  
 Luria-Latarjet effect, 2, 4  
 mismatch repair, 1, 4, 9  
 multiplicity reactivation (MR), 1–5, 7–9,  
 11, 12, 15  
 mutagenesis, 10  
 photoreactivation, 1, 2  
 post-replication recombinational repair  
 (PRRR), 1, 4, 5, 7–9, 15  
 recombinational repair, 2, 15  
 replication repair, 5  
 strand transfer, 10  
 T2, 2, 4, 10  
 T3, 8, 14
- Bacteriophage (*cont.*),  
 T4, 1–16, 218  
 genes/proteins  
*dda*, 9  
*denV* (endonuclease V), 1, 2, 5–10,  
 12–14  
 DNA ligase, *see gene 30*  
 DNA polymerase, *see gene 43*  
 endonuclease V, *see denV*  
 endonuclease VII, *see gene 49*  
*gene 30* (DNA ligase), 2, 4, 6, 9, 14,  
 58  
*gene 32* (SSB), 3, 5–8, 14, 15  
*gene 41*, 5–10  
*gene 43* (DNA polymerase), 4, 6, 15  
*gene 44*, 5, 6  
*gene 45*, 5, 6, 15  
*gene 46*, 3, 6, 8, 14  
*gene 47*, 3, 6, 8, 10, 14  
*gene 49* (endonuclease VII), 4, 8, 9  
*gene 59*, 3, 6, 8, 9  
*rnh*, 3, 6  
 SSB, *see gene 32*  
*uvsW*, 3–6  
*uvsX*, 1, 3–7, 9, 14, 15, 132  
*uvsY*, 3–7, 132, 133
- T5, 4  
 T6, 14  
 T7, 3, 8, 9, 10, 14  
*gene 2.5*, 10  
*gene 3* (endonuclease I), 9  
*gene 4*, 10
- Base excision repair (BER),  
 bacteriophage, 1, 2, 7, 13  
 eukaryotic, 43–69, 87–101, 290, 330, 334,  
 378–381, 390
- Bloom's syndrome, *see* Mammalian BLM

- BRCA1-Associated Surveillance Complex, 250
- Break-induced replication, 135
- Breast cancer (*see also* Mammalian *BRCA1* and *BRCA2*), 225, 226, 237–267
- Budding yeast, *see Saccharomyces cerevisiae*
- Burkitt's lymphoma, 294
- Caenorhabditis elegans*, 127, 148, 222
- Spo11*, 127
- Cell-cycle arrest/delay, *see* Checkpoints
- Cervical carcinoma, 322
- Checkpoints, 56, 61, 68, 155, 156, 164–166, 190, 195, 196, 197, 238, 240–242, 249, 253–257, 295–298, 315–328, 330, 335, 338, 339, 345, 346, 364, 387–390
- Chromosome translocations, *see* Translocations
- Class-switch recombination (CSR), 269, 292, 294, 297, 298
- Cockayne's syndrome (CS; *see also* Transcription-coupled repair), 13, 66, 67, 290, 330, 381
- Crossover recombination
- regulation by *MSH4* and *MSH5*, 137, 138
- Delayed genomic instability, 346
- DNA glycosylase, 43, 45
- adenine-specific DNA glycosylase, 45, 379
- G/T glycosylase, 45
- 3-methyladenine-DNA glycosylase, 45, 290, 338, 379
- , 45, 379
- N-methylpurine/DNA glycosylase, 45
- 8-oxoguanine DNA glycosylase, 45, 178, 379
- thymine DNA glycosylase, 45, 178
- thymine glycol-DNA glycosylase, 45, 379
- uracil DNA glycosylase (UDG), 45, 46, 55, 62, 69, 379
- UV damage, 343
- DNA polymerase
- E. coli* DNA polymerase I, 2
- E. coli* DNA polymerase III ( $\beta$  subunit), 390
- mitochondrial, 59
- pol  $\alpha$ , 47, 137, 341, 345
- pol  $\beta$ , 45–47, 55, 57–60, 63, 66, 67, 69, 380
- pol  $\gamma$ , 48, 59, 6
- pol  $\delta$ , 46, 47, 58, 59, 61, 62, 67, 68, 137, 192, 390
- pol  $\epsilon$ , 46, 47, 58–60, 62, 67, 68, 137, 192
- Double-strand break repair (DSBR; *see also* Homologous recombination; Nonhomologous end-joining), 1, 3, 43, 64, 67, 108–119, 125–139, 147–166, 173, 174, 207–235, 383
- bacteriophage, 1, 3, 9
- donor preference, 117, 118, 179–182
- Double-strand break repair (DSBR) (*cont.*)
- Drosophila*, 178–197
- P elements, 179
- end-processing, 127–131
- heteroduplex DNA formation, 131–137
- resolution of intermediates, 137, 138
- single-strand annealing (SSA), 139, 210, 213, 218, 330–332, 336, 337, 340, 342
- synthesis-dependent strand annealing (SDSA), 182, 183
- Drosophila*, 173–206, 218, 222, 359
- double-strand break repair, 178–197
- P elements, 179
- genes/proteins
- DACPO (p21), 192
- Dmblm*, 193, 194
- Dmmlh1*, 175–177
- Dmmsh6*, 175, 177
- Dmp53*, 196
- Dmpms2*, 175–177
- Dmrad54*, *see okr*
- DmrecQ4*, 194
- DmrecQ5*, 194
- DNA ligase I, 197
- DNA ligase III, 197
- DNA ligase IV, 197
- exo1*, *see Tosca*
- FEN-1*, 192
- FEN1*, 197
- grapes*, 190, 197
- GURKEN, 188
- Ku70* (*Ypbf1b*), 190, 191
- Ku86*, 191, 197
- loki*, 197
- mei-218*, 190
- mei-41*, 188, 190
- mei-9*, 174, 177, 178, 197
- mei-9*, 190
- mei-W68*, 127, 188, 197
- mre11*, 194, 196
- mus209*, *see* PCNA
- mus-304*, 197
- mus309* (*spn-C*), 188–193
- nbs*, 194, 197
- okr* (*okra*), 188, 189
- p21, *see* DACPO
- PARP, 196, 197
- PCNA, 192–193
- RAD1, 197
- RAD17, 197
- RAD21, 197
- rad50*, 194, 196
- RAD9, 197
- ribosomal protein S3, 58

*Drosophila (cont.)*genes/proteins (*cont.*)

- Rrp-1*, 88
- spell1* (spellchecker), 175–177
- spindle*, 187, 188
- spn-B*, 188
- spn-C*, *see mus309*
- spn-D*, 188
- Tosca (exo1)*, 176, 340
- wee1*, 190
- XRCC1*, 197
- Ypbf1b*, *see Ku70*
- gene targeting, 185, 186
- mariner elements, 185, 222
- mismatch repair, 173–178
- nonhomologous end-joining (NHEJ), 179, 186, 187, 282, 287–288, 378

*Escherichia coli*, 12, 13, 21–42

## bacteriophage, 1–19

## genes/proteins

- Ada*, 378
- alkA*, 379
- Dam methylase, 380
- DNA polymerase I, 2
- DNA polymerase III ( $\beta$  subunit), 390
- dnaB*, 22, 24, 34–36
- dnaC*, 22, 24, 34, 36, 37
- dnaG*, 22, 24, 34–36
- dnaN*, 30
- dnaT*, 22, 24, 34–36
- endonuclease III, 5, 379
- exonuclease III (*xth*), 48, 49, 88–90, 94, 96, 380
- formamidopyrimidine-glycosylase, 5
- mug*, 379
- mutH*, 380
- mutL*, 174, 177, 339, 380
- mutS*, 174, 177, 339, 380, 390
- mutY*, 379
- nfo*, 49, 380
- nth*, 379, 380
- Ogt*, 378
- priA*, 22, 24, 26, 34–37
- priB*, 22, 24, 34–36
- priC*, 22, 24, 34–37
- recA*, 6, 12, 14, 15, 21–23, 26, 27, 31–34, 108, 132, 133, 188, 223, 340, 341, 384, 390
- recB*, 12, 23, 24, 26, 28, 130
- recC*, 12, 23, 24, 26, 28, 130
- recD*, 23, 24, 26, 28, 130
- recF*, 21–37, 132
- recG*, 24
- recJ*, 23, 24

*Escherichia coli (cont.)*genes/proteins (*cont.*)

- recN*, 23, 24
- recO*, 22, 24–37, 132, 133
- recQ*, 23, 24, 193, 194
- recR*, 22, 24–37, 132, 133
- rus*, 23
- ruvA*, 23, 24, 333
- ruvB*, 23, 24, 333
- ruvC*, 23, 24, 333
- sbcB*, 26
- sbcC*, 26, 127–129, 149
- sbcD*, 127–129, 149, 151
- SSB, 27, 28, 31–34
- ung*, 379
- uvrA*, 12, 26, 339
- uvrB*, 12
- uvrC*, 12
- uvrD*, 12
- xth*, *see* exonuclease III
- homologous recombination, 22–25
- nucleotide excision repair (NER), 21
- photoreactivation repair, 21
- post-replication (recombinational) repair, 4, 21–42
- primosome assembly, 34–37
- RecFOR, 21–42
  - biochemistry, 31, 32
  - evolutionary conservation, 28–30
  - genetics, 25–30
  - mutant phenotypes, 26–28
  - regulation, 28, 30
- Fanconi anemia, 346
- G1 and G2/M arrest, *see* Checkpoints
- Gene amplification, 223, 320, 330, 346
- Gene targeting, 119, 182, 185, 186, 211, 212, 218, 221
- Genomic instability, *see* Delayed genomic instability; Microsatellite instability
- Hereditary nonpolyposis colorectal cancer (HNPCC), 174, 380
- Holliday junctions (*see also* Homologous recombination), 8, 23, 127, 137, 177
- Homeologous recombination, *see* Homologous recombination, sequence divergence
- Homologous recombination
  - BRCA1, 241, 245–248, 251–253, 256
  - BRCA2, 241, 245–248, 251–253, 256
  - double-strand break-induced, *see* Double-strand break repair
  - E. coli*, 22–25

- Homologous recombination (*cont.*)  
 gene amplification, 223, 320, 330, 346  
 palindromic sequences, 221, 222  
 replication-associated, 21–42, 218, 257,  
 332, 333  
 sequence divergence (homeologous), 220,  
 221, 339, 340, 342, 346  
 somatic hypermutation, 290  
 spontaneous, 329–357  
 transcriptional effects, 221, 342  
 UV-induced, 329–357
- Immunoglobulin (Ig) genes  
 class-switch recombination, 269, 292, 294,  
 297, 298  
 diversification, 272–274  
 somatic hypermutation, 290  
 structure, 270–272  
 V-gene replacement, 291
- Illegitimate recombination, *see*  
 Nonhomologous end-joining
- Li-Fraumeni cancer syndrome (*see also*  
 Mammalian *p53*), 296
- Lymphocyte development, 270–274
- Lymphoid malignancies, 294–297
- Maize, 359
- Mammalian genes/proteins  
 14-3-3 protein, 297  
*APE1*, *see HAP1* and apurinic/  
 apyrimidinic endonuclease  
*APEX*, *see HAP1* and apurinic/  
 apyrimidinic endonuclease  
 apurinic/apyrimidinic endonuclease (AP  
 endo), 45–58, 60, 61, 64, 66, 67,  
 69, 87–105, 197  
 human variants, 52, 53  
*ATM* (*see also* Ataxia telangiectasia), 126,  
 165, 194, 197, 240, 245, 286, 296–  
 298, 315–317, 321, 322, 338, 345,  
 367, 388–390  
*ATR* (*FRP1*), 190, 297, 315–317, 387, 388,  
 390  
*ATXR*, 197  
*BAP1*, 238, 245  
*BARD1*, 238, 244, 245, 247, 248  
 BASC (BRCA1-Associated Surveillance  
 Complex), 250  
*BLM*, 193, 245, 250  
*BRCA1*, 63, 67, 126, 163, 196, 226, 237–267,  
 344, 345, 384, 385  
 checkpoints, 253, 254  
 chromosome stabilization, 254, 255  
 expression, 241  
 homologous recombination, 251–253  
 mutant phenotypes, 241–244
- Mammalian genes/proteins (*cont.*)  
*BRCA1* (*cont.*)  
 overexpression slows tumor growth,  
 242  
 protein interactions, 244–250  
 protein structure, 237–240  
 sensitivity to DNA damage, 243, 244  
 transcription-coupled repair, 250, 251  
*BRCA2*, 126, 138, 139, 163, 226, 237–267,  
 344, 345, 384, 385  
 checkpoints, 253, 254  
 chromosome stability, 254, 255  
 expression, 241  
 homologous recombination, 251–253  
 mutant phenotypes, 241–244  
 protein interactions, 244–250  
 protein structure, 240  
 sensitivity to DNA damage, 243, 244  
 transcription-coupled repair, 250, 251  
*Bub1*, 255  
 casein kinase I, 55  
 casein kinase II, 55  
*Cdc2*, 297, 390  
*Cdk2*, 390  
*Cdk4*, 320, 390  
*CDS1*, 240  
*CHK1*, 197, 297, 388, 389  
*CHK2*, 197, 388–390  
*CIP1*, *see p21*  
 c-myc, 245, 294  
*CSA/CSB*, *see* Cockayne's syndrome  
 cyclin A, 390  
 cyclin D, 390  
 cyclin E, 390  
*DMC1*, 132, 136–138, 188  
 DNA ligase I, 45–47, 60, 61, 64, 69, 285  
 DNA ligase II, 285  
 DNA ligase III, 45–47, 60, 63, 64, 66, 67,  
 69, 285, 380  
 DNA ligase IV, 281, 285, 286, 289, 298,  
 364, 386  
 DNA-PK, 55, 56, 62, 67, 109, 163, 190, 281–  
 287, 289, 294, 297, 298, 345, 363,  
 364, 367–369, 386, 387  
*ERCC1*, 62, 64, 177, 382, 383  
*ERCC2*, *see* XPD  
*ERCC3*, *see* XPB  
*ERCC4*, *see* XPF  
*ERCC5*, *see* XPG  
*EXO1*, 177, 340  
*FANCG* (*XRCC9*), 345, 346  
*FEN1*, 45–48, 59–62, 68  
*FKHR*, 320  
*FRAP* (*mTOR*), 197

Mammalian genes/proteins (*cont.*)

*FRP1*, *see* *ATR*  
*HAP1* (*see also* apurinic/aprimidinic endonuclease), 87–105, 379  
 AP site recognition and binding, 91, 96–98  
 catalytic mechanism, 94, 96  
 expression, 100, 101  
 kinetics of cleavage, 90, 91  
 redox functions, 91–93  
 regulation of p53, 92, 93  
 stress protection, 99  
 structure, 93–99  
 subcellular localization, 99, 100  
 substrates, 89–90  
*HDAC1/2*, 238, 245  
*HHR23B*, 382, 383  
 histone deacetylase complex (HDAC), 238, 245  
*hNth1*, 45, 66, 67  
 Ku (Ku70/Ku80/Ku86), 61, 129, 190, 281–287, 289, 294, 297, 298, 345, 363, 364, 367, 368, 386  
*MDM2*, 320–322  
*MLH1*, 67, 68, 174–176, 245, 250, 339, 380, 381  
*MLH3*, 175  
*MRE11*, 125–139, 147–166, 194, 224, 245, 248–250, 364, 365, 385  
*MRF1*, 317, 318  
*MSH2*, 67, 68, 174, 175, 177, 221, 245, 250, 339, 343, 344, 380, 381  
*MSH3*, 67, 175, 380  
*MSH4*, 175  
*MSH5*, 175  
*MSH6*, 174, 175, 245, 250, 344, 380, 381  
*mTOR*, *see* *FRAP*  
*mTR*, *see* telomerase RNA subunit  
*MYCN*, 320  
*Myf-5*, 317, 318  
*MyoD*, 317–322  
*myogenin*, 317  
*NBS1* (*see also* Nijmegen breakage syndrome), 125–139, 147–166, 194, 224, 245, 248–250, 287, 364, 365, 385  
 nibrin, *see* *NBS1*  
*OGG1*, 177  
*P/CAF*, 245  
*p21* (*WAF1/CIP1*), 48, 61, 68, 192, 242, 243, 317, 319, 322, 388, 390  
*p34*, 382  
*p37*, 48  
*p44*, 382

Mammalian genes/proteins (*cont.*)

*p52*, 382  
*p53* (*see also* Li-Fraumeni syndrome), 51, 56, 92, 93, 119, 138, 163–165, 190, 196, 238, 242, 243, 245, 250, 252, 254, 255, 286, 296–298, 316, 317, 321, 343, 345, 346, 364, 367, 388, 390  
*p62*, 382  
*p95*, *see* *NBS1*  
*p107*, 318  
*PARP*, *see* poly(ADP-ribose)polymerase  
*PAX3*, 320  
*PAX7*, 320  
*PCNA*, *see* proliferating cell nuclear antigen  
*PKC*, *see* protein kinase C  
*PMS1*, 174, 175, 380, 381  
*PMS2*, 68, 174–176, 343, 380, 381  
 poly(ADP-ribose)polymerase (PARP), 43, 48, 58, 62–64, 67, 368, 369  
 proliferating cell nuclear antigen (PCNA), 45, 57, 58–62, 64, 67, 68, 241, 247, 248, 250, 344, 345, 390  
 protein kinase C (PKC), 55, 58, 319  
*RAD50*, 125–139, 147–166, 194, 196, 221, 224, 245, 248–250, 364, 365, 385  
*RAD51*, 111, 132, 137–139, 163, 197, 220, 223, 224, 226, 242, 245–248, 250–253, 255, 256, 334, 345, 384, 385, 389  
 overexpression, 223, 224, 344  
*RAD51B* (*REC2/RAD51L1*), 132, 137, 224, 334, 344, 385  
*RAD51C*, 132, 137, 188, 224, 385  
*RAD51D*, 132, 137, 224, 385  
*RAD51L1*, *see* *RAD51B*  
*RAD52*, 132, 139, 224, 345, 385  
 overexpression, 224  
*RAD54*, 132, 136, 188, 189, 224, 290, 344, 385, 386  
*RAG1/RAG2*, 151, 274–281, 289, 291–295, 298  
*Rb*, 245, 318, 319, 321  
*RbAp46/47*, 245  
*REC2*, *see* *RAD51B*  
*RECQ4*, 193, 194  
*RECQ5*, 193, 194  
*RECQL*, 193  
*Ref-1*, *see* *HAP1*  
 replication factor C (RFC), , 46–48, 58–62, 69, 256  
 replication protein A (RPA), 46–48, 56, 58, 61, 62, 69, 129, 344, 345  
*RFC*, *see* replication factor C

- Mammalian genes/proteins (*cont.*)
- RHA*, *see* RNA helicase A
  - RNA helicase A, 238, 245, 250
  - RPA, *see* replication protein A
  - RPC, 245, 250
  - SAS, 320
  - SPO11*, 127
  - tankyrase, 368, 369
  - TdT, *see* Terminal deoxynucleotidyl transferase
  - telomerase RNA subunit (mTR), 367
  - terminal deoxynucleotidyl transferase (TdT), 281
  - TIN2, 363
  - TRF1, 361, 363, 364, 368, 369
  - TRF2, 222, 361, 364, 368
  - $\gamma$ -tubulin, 245, 254
  - WAF1*, *see* p21
  - WAF1*, *see* p21
  - WRN, 193
  - XPA, 62, 64, 290, 382, 383
  - XPB (*ERCC3*), 64, 66, 290, 381–383
  - XPC, 64, 382, 383
  - XPD (*ERCC2*), 64, 66, 290, 382, 383
  - XPF (*ERCC4*), 62, 64, 177, 197, 381–383
  - XPG (*ERCC5*), 62, 64, 66, 68, 176, 340, 382, 383
  - XRCC1, 45, 46, 48, 63, 66, 67, 380
  - XRCC2, 132, 137, 197, 224, 252, 384, 385
  - XRCC3, 132, 137, 188, 224, 252, 384, 385
  - XRCC4, 281, 283, 285, 286, 289, 298, 364, 386
  - XRCC5, *see* Ku80/Ku86
  - XRCC6, *see* Ku70
  - XRCC7, *see* DNA-PK
  - XRCC9, *see* FANCG
- Mating-type (*Saccharomyces cerevisiae*)
- recombination enhancer (RE), 118
  - regulates chemical/radiation resistance, 109–111
  - regulates recombination, 107–124
    - spontaneous/UV-induced, 111, 112
    - double-strand break-induced, 112–114
  - switching, 107–108, 272
- Methylguanine methyltransferase (MGMT), 378, 390
- E. coli* Ada, 378
  - E. coli* Ogt, 378
  - O6-methylguanine DNA-methyltransferase, 378
  - S. cerevisiae* Mgt1p, 378
- Microsatellite instability, 176, 346
- Mismatch repair (MMR), 67, 68, 225, 291, 332, 337, 339, 340, 343–346, 380, 381, 390
- bacteriophage, 1, 4, 9
  - defects confer tolerance to methylation damage, 176
  - Drosophila*, 173–178
  - extracts, 178
  - microsatellite instability, 176, 346
  - microsatellite spread during double-strand break repair, 214
- MRE11/RAD50/NBS1 complex (mammalian)
- clinical considerations, 163–165
  - cytology, 160–163
  - genetic analysis, 160
- Mre11p/Rad50p/Xrs2p complex (*Saccharomyces cerevisiae*)
- checkpoint functions, 155, 156
  - in vitro activities, 149–151
  - meiotic functions, 152–154
  - mitotic functions, 154, 155
  - mutant analysis, 157, 158
  - nuclease, 156, 157
  - telomere functions, 155, 156
- Muscle differentiation, 317, 318
- inhibition, 320–322
- Neurological development, 285, 286
- Nijmegen breakage syndrome (NBS; *see also* Mammalian NBS1), 126, 129, 148, 162–164, 194, 197, 224, 249, 364, 385
- Nonhomologous end-joining (NHEJ; *see also* Double-strand break repair), 108, 109, 112, 114–118, 125, 147–166, 179, 186, 187, 209, 213–215, 218, 222, 225, 249, 252, 332, 338, 341, 345, 363–366, 369, 384, 386, 387, 390
- competition with homologous recombination, 115–117, 213, 214
  - Drosophila*, 179, 186, 187, 281, 283, 378
  - generation of immune diversity, 269–313
  - illegitimate recombination, 332, 341, 345, 366
  - imprecise, 114–116
  - precise, 114–115
- Nucleosomal DNA, 366
- Nucleotide excision repair (NER; *see also* Transcription-coupled repair), 13, 22–25, 64, 67, 68, 174, 177, 225, 290, 329, 332–336, 339–341, 343–346, 381–383, 390
- E. coli*, 22–25

- Overexpression  
*BRCA1*, 242  
*RAD51*, 223, 224, 344  
*RAD52*, 224
- Photolyase, 330, 343, 377, 378
- Photoreactivation, 1, 2, 21, 330, 377
- Plants, 13  
*Arabidopsis* Arp protein, 88  
 maize, 359
- Post-replication recombinational repair, 4,  
 21–42
- Radioresistant DNA synthesis (RDS), 163,  
 165
- RecFOR, 21–42  
 biochemistry, 31, 32  
 evolutionary conservation, 28–30  
 genetics, 25–30  
 mutant phenotypes, 26–28  
 regulation, 28, 30
- Recombination enhancer (RE), 118
- Repetitive elements, 220
- Rhabdomyosarcomas, 320, 322
- Rothman-Thomson syndrome (*see also* Mam-  
 malian *RECQ4*), 194
- S phase arrest, *see* Checkpoints
- Saccharomyces cerevisiae*  
 genes/proteins  
*APE1*, 380  
*APN1*, 380  
*APN2*, 88, 380  
*BMH1*, 383  
*BMH2*, 383  
 casein kinase II, 156  
*CDC5*, 156  
*CDC9*, *see* ligase I  
*CDC28*, 333  
*CHK1*, 190, 388  
*DDC1*, 388, 389  
*DDC2*, 387, 388  
*DIN7*, 340  
*DMC1*, 14, 15, 111, 126, 132, 136, 137,  
 188  
 DNA ligase IV, *see* *LIG4*  
*DPB11*, 388  
*DUN1*, 194, 197, 335, 338  
*ESR1*, *see* *MEC1*  
*EST1*, 156  
*EST2*, 156  
*ETH1*, *see* *APN2*  
*EXO1*, 335, 340  
*FEN1*, *see* *RAD27*  
*HAP1*, *see* *APE1*
- Saccharomyces cerevisiae* (*cont.*)  
 genes/proteins (*cont.*)  
*HDF1*, *see* *yKU70*  
*HDF2*, *see* *yKU80*  
*HML $\alpha$* , 107, 115–118  
*HMR $\alpha$* , 107, 115, 117, 118  
*HRR25*, 338  
*LIF1*, 109, 115, 386  
*LIG4* (DNA ligase IV), 109, 115, 116  
 ligase I (*CDC9*), 138  
 ligase IV, 138, 386  
*MAG1*, 338  
*MAT*, 107–119, 156, 332  
*MATA1*, 107, 110  
*MAT $\alpha$ 1*, 107  
*MAT $\alpha$ 2*, 107, 110, 118  
*MCM1*, 107, 118  
*MEC1*, 164, 190, 287, 315, 316, 338, 339,  
 387–389  
*MEC3*, 338, 388, 389  
*MEK1*, 194  
*MLH1*, 138, 175, 176, 380  
*MLH2*, 175, 197  
*MLH3*, 175, 197, 380, 381  
*MRE11*, 109, 115, 116, 125–139, 147–  
 166, 194, 287, 364, 366, 385  
*MSH1*, 175  
*MSH2*, 175, 339, 340, 345, 380  
*MSH3*, 175, 197, 339, 340, 345, 380  
*MSH4*, 137, 138, 175, 197  
*MSH5*, 137, 138, 175, 197  
*MSH6*, 175, 380  
*OGG1*, 379  
*PDS1*, 388, 389  
*PMS1*, 175, 380, 381  
*PRP19*, *see* *EXO1*  
*PSO4*, 335, 340  
*RAD1*, 177, 197, 331, 334–340, 346, 382,  
 383  
*RAD2*, 176, 335–337, 340, 382, 383  
*RAD3* (and *RAD3* epistasis group) 108,  
 110, 332–337, 340, 382, 383  
*RAD4*, 335–337, 382, 383  
*RAD5*, 116, 335, 337, 338  
*RAD6* (and *RAD6* epistasis group) 108,  
 110, 332, 335, 337, 340  
*RAD7*, 335–337  
*RAD9*, 335, 338, 339, 388  
*RAD10*, 117, 330, 334–337, 340, 346,  
 382, 383  
*RAD14*, 335–337, 340, 382, 383  
*RAD17*, 335, 338, 388, 389  
*RAD18*, 110, 335, 337, 338

*Saccharomyces cerevisiae* (cont.)

## genes/proteins (cont.)

- RAD23, 335–337, 382, 383  
 RAD24, 335, 338, 339, 388, 389  
 RAD25, *see* SSL1  
 RAD27, 340  
 RAD50, 109, 115, 125–139, 147–166,  
 194, 287, 333, 364, 366, 385  
 RAD51, 28, 108, 110, 111, 126, 131–136,  
 139, 188, 189, 224, 246, 332–335,  
 340, 341, 384  
 RAD52, 26, 28, 31, 108–110, 114, 115,  
 126, 131, 132, 134–136, 139, 154,  
 197, 224, 332–335, 340, 341, 384  
 RAD53, 287, 338, 388, 389  
 RAD54, 108, 110, 111, 126, 131, 132,  
 134–136, 139, 188, 189, 333–335,  
 341, 384  
 RAD55, 26, 28, 110, 126, 131–135, 137,  
 139, 384  
 RAD57, 26, 28, 110, 126, 131–135, 137,  
 139, 197, 384  
 RAD59, 126, 132, 136, 139, 197  
 RAPI, 366  
 RDH54, *see* TID1  
 rem (*rad3*), 333, 337  
 replication protein A (RPA/RFA1), 28,  
 133–135, 340, 341  
 RFA1, *see* replication protein A  
 RME1, 107, 110  
 RNR3, 338  
 SEPI, 340  
 SGS1, 193, 194  
 SIR2, 115, 116, 366  
 SIR3, 115, 116, 366  
 SIR4, 115, 116, 366  
 SNF1, 135  
 SPK1, 194  
 SPO11, 111, 126, 130, 148, 154, 197  
 SPO13, 154  
 SRS2, 131  
 SSL1 (RAD25) 335, 337, 340, 381–383  
 SSL2, 382  
 SSN6, 107  
 SWI2, 135  
 TEL1, 115, 316, 367, 387–389  
 TFB1, 382, 383  
 TFB2, 382, 383  
 TFB4, 382  
 TID1 (RDH54), 111, 117, 126, 131, 132,  
 136  
 topoisomerase, 117  
 TUB1, 333  
 TUP1, 107

*Saccharomyces cerevisiae* (cont.)

## genes/proteins (cont.)

- XRS2, 109, 115, 116, 125–139, 147–166,  
 194, 248, 249, 287, 364, 366, 385  
 yKU70 (HDF1), 109, 114–117, 156, 287,  
 363, 366  
 yKU80 (HDF2), 109, 115, 116, 156, 287,  
 363, 366  
 mating-type  
 recombination enhancer (RE), 118  
 regulates chemical/radiation resis-  
 tance, 109–111  
 regulates recombination, 107–124  
 double-strand break-induced, 112–  
 114  
 spontaneous/UV-induced, 111, 112  
 switching, 107–108, 272  
*Schizosaccharomyces pombe*  
 genes/proteins  
 cdc2, 389  
 cdc25, 297  
 cds1, 388, 389  
 chk1, 388, 389  
 crb2 (*rhp9*), 388  
 cut2, 388, 389  
 cut5 (*rad4*), 388  
 exo1, 177, 340  
 hus1, 387–389  
 mik1, 297  
 MutY homolog, 379  
 PCNA, 389  
 rad1, 387–389  
 rad3, 297, 315, 316, 339, 387, 388  
 rad4, *see* cut5  
 rad9, 387, 389  
 rad13, 382, 383  
 rad15, 382, 383  
 rad16, 382, 383  
 rad17, 387–389  
 rad24, 388  
 rad25, 388  
 rad26, 387, 388  
 rhp9, *see* crb2  
 SPC3D6.10, 88  
 swi10, 382, 383  
 tel1, 387, 388  
 wee1, 297  
 Severe combined immunodeficiency (SCID),  
 274, 281–286, 294, 296, 367, 368  
 Silencing, *see* Sir proteins and Telomeres  
 Sir proteins, 107, 110  
 SIR2, 115, 116, 366  
 SIR3, 115, 116, 366  
 SIR4, 115, 116, 366



- Skin cancer, 329, 343
- Small-cell lung carcinoma, 321
- Somatic hypermutation, 289–291, 297
- no requirement for base-excision repair, 290
  - no requirement for homologous recombination, 290
  - potential role for mismatch repair, 291
  - role for error-prone DNA polymerase, 291
- Structural Maintenance of Chromosome (SMC) family, *see Escherichia coli*, genes and proteins, *sbcC*; *Saccharomyces cerevisiae*, *RAD50*; Mammalian genes/proteins, *RAD50*
- Telomeres, 359–375
- addition, 222, 223
  - associated proteins, 222, 361, 363, 364, 368, 369
    - tankyrase, 368, 369
    - TIN2, 363
    - TRF1, 361, 363, 364, 368, 369
    - TRF2, 361, 364, 368
  - end-capping, 359, 367–369
  - replication, 360–362
  - shortening/length, 130, 155, 156, 165, 190, 255, 360, 361, 366–369
  - silencing/position effect, 366
  - t loops, 222, 361, 365
  - telomerase RNA subunit (mTR), 367
- TFIIH, 382, 383
- Topoisomerase, 3, 6
- topoisomerase I, 6, 43
  - topoisomerase II, 3, 6, 43, 117
- Transcription factors
- AP-1, 51, 91, 93
  - ATF/CREB, 51
  - CtIP, 238, 245
  - DP1, 319, 321
  - E2F1, 319, 321
  - Fos, 51, 91–93
  - HIF $\alpha$ , 51
  - Jun, 51, 91–93, 240
  - Myb, 51
  - NF $\kappa$ B, 51
- Transcriptional activation, 238–241
- Transcription-coupled repair (TCR), 66, 67, 238, 241, 250, 251, 256, 330, 339, 340, 343
- Translesion synthesis, 332, 334, 346
- Translocations (chromosome), 112, 217, 279, 294, 295, 320, 330, 331, 339, 365, 367
- Trichothiodystrophy (TTD), 330, 381, 383
- Tumor suppressors, 138, 225, 226, 237–267, 330
- Ty recombination, 112, 337, 338
- UV-damage endonuclease (UVDE), 330, 336, 337, 343
- UV-induced recombination, 329–357
- V(D)J recombination, 55, 109, 138, 151, 214, 225, 269–313, 363, 364
- V(D)J cleavage, 274–279
- V(D)J joining, 280–286
- Werner's syndrome, *see* Mammalian WRN
- Xenopus laevis*, 46, 59, 69, 282
- Xeroderma pigmentosum (*see also* Mammalian XPA-XPG genes), 13, 64, 66, 330, 343, 381, 383
- X-solvases, 8